LIDDS — Lidds AB Share News
0.000.00%
Last trade - 00:00- SEK3.36m
- SEK1.62m
Brief: Lidds: Anja Peters Becomes New CFO
Brief: Lidds Q1 Pre-Tax Loss Widens To SEK 2.5 Million
Brief: Lidds: Liproca Depot Open Label Extension Study Indicates Longer Treatment Intervals
Brief: Lidds Nanozolid Technology Receives US Patent Valid Until 2037
Brief: Lidds To Evaluate Possible Listing On Nasdaq Stockholm's Main Market During 2020
Brief: Lidds: Collaboration With Belina Pharma Concludes
Brief: Lidds Q4 Pre-Tax Loss Widens To SEK 4.9 Million
Brief: Lidds Adds Another Scandinavian Clinic To The NZ-DTX-001 Clinical Trial
Brief: LIDDS AB Q3 Pre-Tax Result Turns To Profit Of Sek 5.4 Million
Brief: LIDDS Adds Two Major University Clinics In Lithuania To Speed Up Enrollment In Ongoing Phase IIb Study
Brief: Lidds Receives Approval From MPA To Start Phase I Study NZ-DTX-001
Brief: Lidds Q2 Pre-Tax Loss Widens To SEK 2.2 Million
Brief: Lidds: Sting Study Opens Up Multi-Billion Dollar Cancer Immunotherapy Market
Brief: LIDDS Receives Patent Approval In Europe
Brief: Lidds Signs License Agreement For Prostate Cancer
Brief: Lidds Q1 Pre-Tax Loss Widens To SEK 2.0 Million
Brief: Lidds Broadens Scope Of Its Technology Platform By Verifying Nanozoli® As Subcutaneous Depot For Systemic Delivery
Brief: Lidds: Positive Effects Of NanoZolid Formulation With STING
Brief: Lidds AB Q4 Pre-Tax Loss At SEK 2.2 Million